Secondary NOD/SCID mice repopulation of 5azaD/TSA treated ex vivo expanded cord blood cells
| . | Primary transplants . | Secondary transplants . | ||
|---|---|---|---|---|
| Human cell dose* . | Primary mouse BM chimerism, % human . | Human cell dose† . | Secondary mouse BM chimerism, % human . | |
| No. 1 | 1.0 × 106 | 5.2 | 5.0 × 105 | 0.21 |
| No. 2 | 1.0 × 106 | 13.1 | 1.4 × 106 | 1.5 |
| No. 3 | 5.0 × 105 | 2.6 | 4.2 × 105 | ND |
| No. 4 | 5.0 × 105 | 48.4 | 5.0 × 106 | 0.60 |
| No. 5 | 5.0 × 105 | 11.2 | 1.4 × 106 | 0.20 |
| No. 6 | 2.5 × 105 | 22.8 | 2.6 × 106 | 0.12 |
| . | Primary transplants . | Secondary transplants . | ||
|---|---|---|---|---|
| Human cell dose* . | Primary mouse BM chimerism, % human . | Human cell dose† . | Secondary mouse BM chimerism, % human . | |
| No. 1 | 1.0 × 106 | 5.2 | 5.0 × 105 | 0.21 |
| No. 2 | 1.0 × 106 | 13.1 | 1.4 × 106 | 1.5 |
| No. 3 | 5.0 × 105 | 2.6 | 4.2 × 105 | ND |
| No. 4 | 5.0 × 105 | 48.4 | 5.0 × 106 | 0.60 |
| No. 5 | 5.0 × 105 | 11.2 | 1.4 × 106 | 0.20 |
| No. 6 | 2.5 × 105 | 22.8 | 2.6 × 106 | 0.12 |
Murine BM from engrafted primary recipients was harvested, and unfractionated murine BM cells were injected into secondary NOD/SCID recipients. BM from primary and secondary recipients was stained for human CD45, CD71, CD19, CD33, CD34, and CD41 to assess multilineage human hematopoietic engraftment after 7 weeks of transplantation.
ND indicates not detectable.
Cells injected in the primary mouse were cultured for 9 days pretreated with 5azaD/TSA (approximately 50% of these cells express CD34).
Cell dose is based on human CD45+ cells.